Basic Information
RNALocate ID: | RLID:11001427 |
RNA Symbol: | hsa-miR-182-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-182 |
RNA ID: | miRBase:MIMAT0000259 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 27278097 |
Tissue/Cell Line: | Bronchoalveolar lavage fluid|Pooled sera |
Method: | miRNA array|qRT-PCR |
MiRNAs involved in endothelial activation miR-92a and inflammation miR-182, AMR miR-142-5p, and Th 17 activation miR-155 in exosomes derived from sera and BAL fluid from BOS LTxRs compared with stable LTxRs. (y axis: relative fold change; x axis: sample source). Originally published in Am J Transplant. Gunasekaran M, et al, 2017. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | qRT-PCR demonstrated significant upregulation of miR-92a (p<0.013) and miR-182 (p<0.020) in AR LTxRs compared with stable LTxRs, and significant upregulation of miR-92a (p<0.041), miR-182 (p<0.012), miR-142-5p (p<0.015), and miR-155 (p<0.002) in BOS LTxRs compared with stable LTxRs. Similarly, exosomes derived from BAL fluid showed significant upregulation of miR-92a (p<0.014) and miR-182 (p<0.026) in AR LTxRs compared with stable LTxRs, and significant upregulation of miR-92a (p<0.024), miR-182 (p<0.026), miR-142-5p (p<0.026), and miR-155 (p<0.008) in BOS LTxRs compared with stable LTxRs (Figure 7). This shows that miRNAs involved in inflammation and endothelial activation were significantly increased in both AR and BOS LTxRs, and that the IL17 pathway was activated in BOS LTxRs. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001634 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001635 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001636 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001637 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
RLID:01001638 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11001426 | Exosome | Pooled sera | 27278097 |
RLID:11001428 | Exosome | Human milk | 28688106 |
RLID:11001429 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11001430 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
RLID:11001431 | Exosome | Renal cancer cells | 21670082 |
RLID:11001432 | Exosome | Breast milk | 22211110 |
RLID:11001433 | Exosome | Brain tissue | 23382797 |
RLID:11001434 | Exosome | Plasma | 23663360 |
RLID:11001435 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001436 | Microvesicle | Seminal plasma | 23539611 |
RLID:11001437 | Microvesicle | Serum | 24797360 |
RLID-D:11000052 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Tongue tissue | |
RLID-D:11000321 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-182-5p | Oral squamous cell carcinoma | MNDR-E-MI-20345 |
MNDR | hsa-miR-182-5p | Large cell neuroendocrine cancer | MNDR-E-MI-20346 |
MNDR | hsa-miR-182-5p | Medulloblastoma | MNDR-E-MI-20347 |
MNDR | hsa-miR-182-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-20348 |
MNDR | hsa-miR-182-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-20349 |
MNDR | hsa-miR-182-5p | Ovarian clear cell carcinoma | MNDR-E-MI-20350 |
MNDR | hsa-miR-182-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-20351 |
MNDR | hsa-miR-182-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-20352 |
MNDR | hsa-miR-182-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-20353 |
MNDR | hsa-miR-182-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-20354 |
MNDR | hsa-miR-182-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-20355 |
MNDR | hsa-miR-182-5p | Her2-receptor positive breast cancer | MNDR-E-MI-20356 |
MNDR | hsa-miR-182-5p | Triple negative breast cancer | MNDR-E-MI-20357 |
MNDR | hsa-miR-182-5p | Breast cancer luminal | MNDR-E-MI-20358 |
MNDR | hsa-miR-182-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-20359 |
MNDR | hsa-miR-182-5p | Hearing loss central | MNDR-E-MI-20360 |
MNDR | hsa-miR-182-5p | Sensorineural hearing loss | MNDR-E-MI-20361 |
MNDR | hsa-miR-182-5p | Small intestine cancer | MNDR-E-MI-20362 |
MNDR | hsa-miR-182-5p | Prostate cancer | MNDR-E-MI-20363 |
MNDR | hsa-miR-182-5p | Gastric cancer | MNDR-E-MI-20364 |
MNDR | hsa-miR-182-5p | Gastric lymphoma | MNDR-E-MI-20365 |
MNDR | hsa-miR-182-5p | Alzheimer disease | MNDR-E-MI-20366 |
MNDR | hsa-miR-182-5p | Bladder cancer | MNDR-E-MI-20367 |
MNDR | hsa-miR-182-5p | Head and neck cancer | MNDR-E-MI-20368 |
MNDR | hsa-miR-182-5p | Ataxia telangiectasia | MNDR-E-MI-20369 |
MNDR | hsa-miR-182-5p | Cardiovascular disease | MNDR-E-MI-20370 |
MNDR | hsa-miR-182-5p | Lung cancer | MNDR-E-MI-20371 |
MNDR | hsa-miR-182-5p | Down syndrome | MNDR-E-MI-20372 |
MNDR | hsa-miR-182-5p | Parkinson disease | MNDR-E-MI-20373 |
MNDR | hsa-miR-182-5p | Basal-like breast cancer | MNDR-E-MI-20374 |
MNDR | hsa-miR-182-5p | Neuroendocrine neoplasia | MNDR-E-MI-20375 |
MNDR | hsa-miR-182-5p | Thyroid cancer | MNDR-E-MI-20376 |
MNDR | hsa-miR-182-5p | Pituitary neoplasms | MNDR-E-MI-20377 |
MNDR | hsa-miR-182-5p | Pancreatic cancer | MNDR-E-MI-20378 |
MNDR | hsa-miR-182-5p | Melanoma | MNDR-E-MI-20379 |
MNDR | hsa-miR-182-5p | Rectum adenocarcinoma | MNDR-E-MI-20380 |
MNDR | hsa-miR-182-5p | Nephroblastoma | MNDR-E-MI-20381 |
MNDR | hsa-miR-182-5p | Colon cancer | MNDR-E-MI-20382 |
MNDR | hsa-miR-182-5p | Colon adenocarcinoma | MNDR-E-MI-20383 |
MNDR | hsa-miR-182-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-20384 |
MNDR | hsa-miR-182-5p | Familial ovarian cancer | MNDR-E-MI-20385 |
MNDR | hsa-miR-182-5p | Hereditary spastic paraplegia | MNDR-E-MI-20386 |
MNDR | hsa-miR-182-5p | Prostate adenocarcinoma | MNDR-E-MI-20387 |
MNDR | hsa-miR-182-5p | Kidney cancer | MNDR-E-MI-20388 |
MNDR | hsa-miR-182-5p | Adenocarcinoma | MNDR-E-MI-20389 |
MNDR | hsa-miR-182-5p | Carcinoma ductal breast | MNDR-E-MI-20390 |
MNDR | hsa-miR-182-5p | Invasive ductal carcinoma | MNDR-E-MI-20391 |
MNDR | hsa-miR-182-5p | Glioblastoma | MNDR-E-MI-20392 |
MNDR | hsa-miR-182-5p | Astrocytoma | MNDR-E-MI-20393 |
MNDR | hsa-miR-182-5p | Glioma | MNDR-E-MI-20394 |
MNDR | hsa-miR-182-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-20395 |
MNDR | hsa-miR-182-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-20396 |
MNDR | hsa-miR-182-5p | Epilepsy temporal lobe | MNDR-E-MI-20397 |
MNDR | hsa-miR-182-5p | Osteosarcoma | MNDR-E-MI-20398 |
MNDR | hsa-miR-182-5p | Liposarcoma | MNDR-E-MI-20399 |
MNDR | hsa-miR-182-5p | Breast carcinoma | MNDR-E-MI-20400 |
MNDR | hsa-miR-182-5p | Uterine cancer | MNDR-E-MI-20401 |
MNDR | hsa-miR-182-5p | Gastric adenocarcinoma | MNDR-E-MI-20402 |
MNDR | hsa-miR-182-5p | Cervical squamous cell carcinoma | MNDR-E-MI-20403 |
MNDR | hsa-miR-182-5p | Pituitary adenoma | MNDR-E-MI-20404 |
MNDR | hsa-miR-182-5p | Lung squamous cell carcinoma | MNDR-E-MI-20405 |
MNDR | hsa-miR-182-5p | Lung adenocarcinoma | MNDR-E-MI-20406 |
MNDR | hsa-miR-182-5p | Thyroid carcinoma | MNDR-E-MI-20407 |
MNDR | hsa-miR-182-5p | Ovarian carcinoma | MNDR-E-MI-20408 |
MNDR | hsa-miR-182-5p | Bladder urothelial carcinoma | MNDR-E-MI-20409 |
MNDR | hsa-miR-182-5p | Pancreatic adenocarcinoma | MNDR-E-MI-20410 |
MNDR | hsa-miR-182-5p | Carcinoma renal cell | MNDR-E-MI-20411 |
MNDR | hsa-miR-182-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-20412 |
MNDR | hsa-miR-182-5p | Chromophobe renal cell carcinoma | MNDR-E-MI-20413 |
MNDR | hsa-miR-182-5p | Large cell carcinoma | MNDR-E-MI-20414 |
MNDR | hsa-miR-182-5p | Cholangiocarcinoma | MNDR-E-MI-20415 |
MNDR | hsa-miR-182-5p | Esophageal cancer | MNDR-E-MI-20416 |
MNDR | hsa-miR-182-5p | Oncocytoma | MNDR-E-MI-20417 |
MNDR | hsa-miR-182-5p | Lung small cell carcinoma | MNDR-E-MI-20418 |
MNDR | hsa-miR-182-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-20419 |
MNDR | hsa-miR-182-5p | Heart failure | MNDR-E-MI-20420 |
MNDR | hsa-miR-182-5p | Breast invasive carcinoma | MNDR-E-MI-20421 |
MNDR | hsa-miR-182-5p | Hepatocellular carcinoma | MNDR-E-MI-20422 |
MNDR | hsa-miR-182-5p | Familiar ovarian carcinoma | MNDR-E-MI-20423 |
MNDR | hsa-miR-182-5p | B-cell lymphoma | MNDR-E-MI-20424 |
MNDR | hsa-miR-182-5p | Rheumatoid arthritis | MNDR-E-MI-20425 |
MNDR | hsa-miR-182-5p | T-cell leukemia | MNDR-E-MI-20426 |
MNDR | hsa-miR-182-5p | Retinoblastoma | MNDR-E-MI-20427 |
MNDR | hsa-miR-182-5p | Hodgkin lymphoma | MNDR-E-MI-20428 |
MNDR | hsa-miR-182-5p | Burkitt lymphoma | MNDR-E-MI-20429 |
MNDR | hsa-miR-182-5p | Crohn disease | MNDR-E-MI-20430 |
MNDR | hsa-miR-182-5p | Neuromyelitis optica | MNDR-E-MI-20431 |
MNDR | hsa-miR-182-5p | Acute myelocytic leukemia | MNDR-E-MI-20432 |
MNDR | hsa-miR-182-5p | Colorectal cancer | MNDR-E-MI-20433 |
MNDR | hsa-miR-182-5p | Multiple myeloma | MNDR-E-MI-20434 |
MNDR | hsa-miR-182-5p | Acute lymphocytic leukemia | MNDR-E-MI-20435 |
MNDR | hsa-miR-182-5p | Ovarian epithelial cancer | MNDR-E-MI-20436 |
MNDR | hsa-miR-182-5p | Uterine cervical neoplasms | MNDR-E-MI-20437 |
MNDR | hsa-miR-182-5p | Ependymoma | MNDR-E-MI-20438 |
MNDR | hsa-miR-182-5p | Lung | MNDR-E-MI-20439 |
MNDR | hsa-miR-182-5p | Prostatic neoplasms | MNDR-E-MI-20440 |
MNDR | hsa-miR-182-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-20441 |
MNDR | hsa-miR-182-5p | Stroke lacunar | MNDR-E-MI-20442 |
MNDR | hsa-miR-182-5p | Breast cancer her3+ negative | MNDR-E-MI-20443 |
MNDR | hsa-miR-182-5p | Duke A | MNDR-E-MI-20444 |
MNDR | hsa-miR-182-5p | Low grade dysplastic nodule | MNDR-E-MI-20445 |
MNDR | hsa-miR-182-5p | Non-sonic hedgehog-medulloblastoma | MNDR-E-MI-20446 |
MNDR | hsa-miR-182-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-20447 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ADAMTS9-AS2 | Homo sapiens | RR00042742 |
TOP